- The former CEO of Activ Surgical and Olympus medical president joins Rob Surgical with the aim of driving an ambitious growth plan to enter hospitals by 2024.
- Todd Usen’s experience will be fundamental in the production and commercialisation stage of its open platform Bitrack System, which has just announced satisfactory results in its clinical trials in patients at the Hospital Clínic de Barcelona.
Barcelona, 18th July 2023.- Rob Surgical today announced the appointment of Todd Usen to its Board of Directors. Todd will work side by side with CEO, Jaume Amat, as the company’s lead operating director. The company, which has just announced the satisfactory results of its clinical trials, which have been carried out at the Hospital Clínic de Barcelona, will enter hospitals in 2024, after receiving European certification to commercialise its open platform Bitrack System.
Todd is a highly respected healthcare executive with extensive experience in scaling and corporate governance. Todd has previously worked as Chairman, Non-Executive Director and CEO leading organizations from technology concept to FDA and CE mark clearance over the last 25 years.
Todd is an executive leader skilled in building, restructuring and growing commercial and operational organizations in both top and bottom line. Responsible for developing and directing both short and long-term strategic vision, product development, logistics, distribution, go-to-market strategy, and M&A activities.
Todd is currently the President and CEO of Minerva Surgical, a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. Also, he is a current board director of Alesi Surgical, MassMedic and SAGES’ Surgical Disruptive Technology Summit.
Mr. Usen has extensive commercial and operational experience with a proven track record of leading large, complex global businesses across several highly-regarded medical device companies. He most recently spent the last four years as the Chief Executive Officer of Activ Surgical, a digital surgery company focused on advanced surgical imaging and AI, where he oversaw the FDA/CE clearance of its ActivSight technology, as well as leading four fundraising rounds totaling over $92 million. From 2015 to 2018, Mr. Usen was President, Medical Systems Group, for Olympus Corporation of the Americas, where he took charge of a complex $2B+ business and restructured the company for leaner growth and investment, drove successful mergers and acquisitions activity, led the expansion from 6 medical divisions to 11 in 3.5 years. Prior to that, Mr. Usen served in executive positions including President, United States Orthopedics, Senior Vice President & General Manager, Joint Reconstruction, and Senior Vice President Sports Medicine at Smith and Nephew, and Vice President Sales at Boston Scientific Corporation. Mr. Usen holds a BS in Marketing from the Isenberg School at the University of Massachusetts and did his MBA work at Pepperdine University.
From this experience he will bring to Rob Surgical strong capabilities to lead the company’s move into commercialisation and production of its open platform, Bitrack System.
Having now completed the FIH clinical trials using Bitrack in collaboration with Hospital Clínic de Barcelona, Rob Surgical plans to further accelerate its expansion in hospitals in 2024, driven by Todd’s strong leadership.
“I am grateful for the opportunity to work with Jaume Amat and the Rob Surgical team to help pave the way for a future where advanced technology and human expertise converge seamlessly. Surgeon’s should have the opportunity to utilise both their laparosopic skills and robotic precision during the same surgery to provide the patient the most optimal outcome. Rob Surgical’s unique blend of cutting-edge robotics and human-centric approach will empower surgeons to achieve unparalleled precision, efficiency, and patient outcomes.” says Todd Usen.
“Todd’s appointment is part of Rob Surgical’s growth plan. Following the successful results of the clinical trials with Hospital Clínic de Barcelona, it is a privilege to add Todd’s talent, energy and experience. Todd is an experienced professional who shares our purpose, to universalise precision surgery and bring its benefits to hospitals, surgeons and patients worldwide. We look forward to working closely with Todd to bring Rob Surgical to the next level”, highlights Jaume Amat, CEO of Rob Surgical.
